Loading content…
ConditionICD-10: I25
Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of death in the United States, accounting for ~700,000 deaths annually. It includes coronary artery disease (the most common form), heart failure, stroke, peripheral artery disease, and atrial fibrillation. Obesity and type 2 diabetes both dramatically increase CVD risk — and certain GLP-1 medications have demonstrated independent cardiovascular benefit beyond their weight-loss and glucose-lowering effects, leading to specific FDA-approved cardiovascular indications.
Key facts
- •CVD causes ~700,000 US deaths per year — leading cause of death
- •Wegovy FDA-approved (March 2024) to reduce risk of major cardiovascular events in adults with overweight/obesity + established CVD
- •Ozempic + Trulicity FDA-approved for cardiovascular risk reduction in type 2 diabetes
- •SELECT trial showed Wegovy reduced MACE (major adverse cardiovascular events) by 20% over ~3 years
- •Cardiovascular benefit appears independent of weight loss — direct vascular effects + inflammation reduction
- •Most US adults underestimate their personal CVD risk
Why GLP-1 medications
GLP-1 medications produce cardiovascular benefit through multiple overlapping mechanisms: weight loss reduces afterload and improves metabolic profile; glucose control reduces vascular damage in diabetic patients; direct vascular effects include reduced inflammation, improved endothelial function, and modest blood-pressure reduction. The SELECT trial (2023 NEJM) demonstrated Wegovy reduced major adverse cardiovascular events by 20% over 33 months in patients with overweight/obesity + established CVD — leading to FDA approval of a specific cardiovascular indication for Wegovy in March 2024. Similar trials drove earlier FDA cardiovascular indications for Ozempic, Trulicity, and Victoza in type 2 diabetes populations.
